ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 8
Outpatient CAR T Therapy and Expanding Access
Panelists discuss strategies for managing transitions of care for chimeric antigen receptor (CAR) T-cell therapy patients, including monitoring for long-term toxicities as well as the feasibility and logistics of administering CAR T therapy in the outpatient vs inpatient setting.
Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Molina: As your patients transition back to the community setting following their initial CAR T-cell infusion and monitoring phase, what steps do you take in the transitions of care process? Do you continue to monitor these patients, and how do you communicate with community providers to ensure they monitor for potential long-term CAR T-cell toxicities?
- Dr. O’Dwyer to Dr. Shaughnessy: At your institution, are patients receiving CAR T-cell therapy in the outpatient or inpatient setting? How feasible is it to administer CAR T-cell therapy in the outpatient setting?
- Resource link: Othman T et al. Outpatient brexu-cel MCL and ALL safe and feasible. ASH 2024 poster abstract or see Appendix 9